Clinical characteristics, risk factors, and outcomes of POEMS syndrome
A longitudinal cohort study
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin lesions) is a paraneoplastic disorder resulting in severe neurologic disability. Understanding the clinical, laboratory, neurophysiologic, and histopathologic features as well as treatment responses of POEMS will assist in more accurate and timely diagnosis, risk stratification, and effective management.
Methods This was a retrospective longitudinal cohort study from 1998 to March 2019, with 7,184 person-months of follow-up time. Hospital databases were used to collate presenting features, investigations, therapies, and response.
Results One hundred patients were included with a median follow-up time of 59 months (range, 1–252). Mean symptom onset to diagnosis was 15 months (range, 1–77), with 54% of patients initially misdiagnosed with chronic inflammatory demyelinating polyneuropathy. Median number of multisystem features at diagnosis was 7. Ninety-six (96%) presented with neuropathy, which was length-dependent in 93 (93%) and painful in 75 (75%). At diagnosis, 35% of patients were wheelchair or bedbound, with median Overall Neuropathy Limitation Score of 6, improving to 3 following treatment (p < 0.05). Five-year survival was 90% and 82% at 10 years, with 5- and 10-year progression-free survival of 65% and 53%. Nontreatment with autologous stem cell transplantation, nonhematologic response, and non–vascular endothelial growth factor response are significant risk factors in multivariate analysis to predict progression or death. Risk factors are incorporated to develop a risk score enabling stratification of high- and low-risk cases.
Conclusions POEMS syndrome is a rare multisystem condition with delayed diagnosis and poor neurologic function at presentation. Therapy has favorable outcomes. Patients at high risk of death or progression can be identified, which may allow for more active monitoring and influence management.
Glossary
- ASCT=
- autologous stem cell transplantation;
- CI=
- confidence interval;
- CIDP=
- chronic inflammatory demyelinating polyneuropathy;
- CR=
- complete response;
- HR=
- hazard ratio;
- IQR=
- interquartile range;
- M-protein=
- monoclonal protein;
- mRS=
- modified Rankin Scale;
- NE=
- not evaluable;
- NR=
- no response;
- ONLS=
- Overall Neuropathy Limitation Score;
- OS=
- overall survival;
- PFS=
- progression-free survival;
- PR=
- partial response;
- SFLC=
- serum free light chains;
- SPE=
- serum protein electrophoresis;
- SUV=
- standardized uptake value;
- sVEGF=
- serum vascular endothelial growth factor;
- UCLH=
- University College London Hospital;
- VEGF=
- vascular endothelial growth factor
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received July 17, 2019.
- Accepted in final form December 27, 2019.
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
- Author response: Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study
- Stephen Keddie, Neurology SpR, Research Fellow, University College London Hospital National Hospital for Neurology and Neurosurgery
- Michael P. Lunn, Professor of Neurology & Neuroimmunology Laboratory Clinical Lead, University College London Hospital National Hospital for Neurology and Neurosurgery
Submitted August 06, 2020 - Reader response: Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study
- Chiara Briani, Neurologist, Department of Neurosciences, University of Padova (Padova, Italy)
- Renzo Manara, Neuroradiologist, Neuroradiology, University of Padova (Padova, Italy)
- Annalisa Angelini, Pathologist, Cardiovascular Pathology, University of Padova (Padova, Italy)
Submitted July 21, 2020
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.